Skip to content
DataLookout
Menu

NCT07027423

BOLD-100 Plus Doxorubicin in Advanced Soft Tissue Sarcomas

StatusWithdrawn
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Stopped Withdrawn before enrolling Sponsor's reason: Unable to finalize the Clinical Trial Agreement with the drug manufacturer BOLD Therapeutics. Show 5 more changesShow less
    • Enrollment target: estimated 32 to confirmed 0
    • Eligibility criteria expanded, about 6 words
    • Interventions: BOLD-100 (Drug), BOLD-100 (Drug), Doxorubicin 75 mg/m^2 (Drug), Doxorubicin 75 mg/m^2 (Drug) to BOLD-100 (Drug), BOLD-100 (Drug), Doxorubicin 75 mg/m^2 (Drug), Doxorubicin 75 mg/m^2 (Drug)
    • Secondary endpoints: details revised at 1 of 4 entries
    • Site details revised
  2. Notable Start date: Jun 30, 2025 to Mar 30, 2026v2
  3. Study First Submitted
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed

Endpoints

Primary

The incidence of dose limiting toxicities (DLTs)
Timeframe: Entire duration of Cycle 1 (21 day cycle)
The rate of Adverse Events (AE)
Timeframe: time the consent form is signed through 12 months following cessation of treatment
Rate of toxicities
Timeframe: time the consent form is signed through 12 months following cessation of treatment.
Participant Quality of Life
Timeframe: pre-dose, Cycle 2 Day1, Cycle 7 Day 1, Cycle 12 Day 1 (21 day cycles)

Secondary (2)

Progression-free survival (PFS)
Analysis of pharmacokinetic parameters of doxorubicin and BOLD-100

Arms and interventions

BOLD-100 and Doxorubicin Dose Level -1Experimental

Escalation phase DL-1 - BOLD-100 230mg/m\^2 + Doxorubicin

BOLD-100 and Doxorubicin Dose Level 1Experimental

Escalation phase DL1 - BOLD-100 420mg/m\^2 + Doxorubicin

BOLD-100 and Doxorubicin Dose Level 2Experimental

Escalation phase DL2 - BOLD-100 500mg/m\^2 + Doxorubicin

BOLD-100 and Doxorubicin Dose Level 3Experimental

Escalation phase DL3 - BOLD-100 625mg/m\^2 + Doxorubicin

BOLD-100 and DoxorubicinExperimental

Exapsnion: BOLD-100 (RP2D) and Doxorubicin

Drugs: BOLD-100, Doxorubicin 75 mg/m^2

Sites

1 site in 1 country

  • UHN- Princess Margaret Cancer CenterToronto, Ontario, Canada